2017

CT-P13 or infliximab originator in immune mediated inflammatory diseases

Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)

ADA vs AZA in postop recurrence in CD

Tofacitinib in UC

Efficacy and Safety of Oral Budesonide in Patients with Active Crohn’s Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study

Phase 2 trial Risankizumab in Crohn’s disease

Adalimumab +/- azathioprine tight control vs clincal management in CD

Topical tacrolimus in UC proctitis

Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial

PF-00547659 in UC